Differences in acute response team call triggering with CREWS scoring: A retrospective analysis Source: International Congress 2015 – Acute critical care: COPD, muscles and weaning Year: 2015
The therapeutic strategies in severe and very severe COPD: a cost-efficacy analysis in Italy Source: Eur Respir J 2006; 28: Suppl. 50, 31s Year: 2006
Potential protective role of prior to diagnosis antibiotic treatment in community-acquired pneumonia: Clinical presentation and outcomes Source: Annual Congress 2011 - Antimicrobial treatment and resistance in lower respiratory tract infections Year: 2011
COPD guidelines in relation to infections: a critical analysis Source: Annual Congress 2008 - PG1 - EU GRACE network full-day course: Antibiotics or not: from acute bronchitis to acute exacerbation of chronic bronchitis Year: 2008
COPD guidelines in relation to infections: a critical analysis Source: Breathe 2009; 5: 317-321 Year: 2009
Critical steps: An evaluation of critical handling errors with DPI use in Greece Source: International Congress 2016 – Screening, diagnosis, assessment, and treatment of COPD in primary care Year: 2016
Relationship between prior triple therapy use and benefits of budesonide/glycopyrronium/formoterol on exacerbation risk: analysis from ETHOS Source: Virtual Congress 2021 – COPD pharmacology: from basic science to real-world data Year: 2021
Definition, treatment and prevention of exacerbations Source: International Congress 2016 – GOLD: novel approaches to COPD assessment and management Year: 2016
Efficacy of using special software “Optimization of medication choice for treatment of patient with comorbidity” (SS) for management of patients with community-acquired pneumonia (CAP) and cardiovascular disease Source: International Congress 2019 – M-health/e-health I Year: 2019
Benefits of triple therapy in moderate, severe, and very severe COPD: subgroup analysis of the ETHOS trial Source: Virtual Congress 2021 – Inhaled treatments for COPD: clinical trials and real-world studies Year: 2021
Severe asthma: approach to diagnosis and treatment Source: Annual Congress 2008 - PG4 - Paediatric respiratory medicine: wheezing children: asthma and beyond Year: 2008
Factors affecting patients’ decision to adjust treatment; secondary analysis of a randomised trial of treatment optimisation in patients with severe asthma Source: Virtual Congress 2021 – Asthma burden and management I Year: 2021
Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: A randomized clinical trial Source: International Congress 2015 – Acute critical care: news from the ICU Year: 2015
Development of a tool to measure the clinical response to biologic therapy in uncontrolled severe asthma: the FEOS score. Source: Virtual Congress 2021 – Severe asthma: evaluation using patient-reported outcome measures (PROMs) and biomarkers, comorbidities and treatments Year: 2021
7-day course of antibiotics had similar efficacy to prolonged course in severe community-acquired pneumonia: a propensity-adjusted analysis Source: Annual Congress 2010 - Aetiology of lower respiratory tract infections and treatment in special situations Year: 2010
Combination therapy versus separate therapy in real-life primary care asthma patients Source: International Congress 2015 – Management of asthma and other respiratory diseases in primary care Year: 2015
Managing tuberculosis in chronic kidney disease: An evaluation of patient treatment regimens Source: Annual Congress 2011 - Tuberculosis in special populations Year: 2011
Integrated care pathways significantly reduce drug dosing and administration errors in patients with acute asthma Source: Eur Respir J 2006; 28: Suppl. 50, 481s Year: 2006
Can we use a biomarker to guide antibiotic treatment in severe COPD exacerbations? Source: Breathe, 15 (4) 353; 10.1183/20734735.0257-2019 Year: 2019